Pesquisar
Alnylam Pharmaceuticals Inc
ALNYAdicionar à lista de desejos
293.626USD
+1.596+0.55%
Horário de mercado （ET）Cotações atrasadas em 15 min
39.18BValor de mercado
71.87P/L TTM
Mais detalhes de Alnylam Pharmaceuticals Inc Empresa
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.
Informações de Alnylam Pharmaceuticals Inc
Código da empresaALNY
Nome da EmpresaAlnylam Pharmaceuticals Inc
Data de listagemMay 28, 2004
CEOGreenstreet (Yvonne L)
Número de funcionários2230
Tipo de títulosOrdinary Share
Fim do ano fiscalMay 28
Endereço675 W Kendall St
CidadeCAMBRIDGE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02142-1168
Telefone16175518200
Sitehttps://www.alnylam.com/
Código da empresaALNY
Data de listagemMay 28, 2004
CEOGreenstreet (Yvonne L)
Executivos da empresa Alnylam Pharmaceuticals Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Yvonne L. Greenstreet, M.D.
Dr. Yvonne L. Greenstreet, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
56.38K
+7.29%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
39.68K
+0.24%
Mr. Tolga Tanguler
Mr. Tolga Tanguler
Chief Commercial Officer
Chief Commercial Officer
15.33K
+5.62%
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
3.64K
-21.31%
Dr. Margaret A. Hamburg, M.D.
Dr. Margaret A. Hamburg, M.D.
Independent Director
Independent Director
136.00
-569.85%
Mr. David E. I. Pyott, CBE
Mr. David E. I. Pyott, CBE
Independent Director
Independent Director
--
--
Ms. Amy W. Schulman, J.D.
Ms. Amy W. Schulman, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Pushkal P. Garg, M.D.
Dr. Pushkal P. Garg, M.D.
Executive Vice President, Chief Research and Development Officer
Executive Vice President, Chief Research and Development Officer
--
--
Ms. Colleen F. Reitan
Ms. Colleen F. Reitan
Independent Director
Independent Director
--
--
Dr. Kevin Fitzgerald, Ph.D.
Dr. Kevin Fitzgerald, Ph.D.
Executive Vice President, Chief Scientific Officer, Head - Early Research and Early Development
Executive Vice President, Chief Scientific Officer, Head - Early Research and Early Development
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Yvonne L. Greenstreet, M.D.
Dr. Yvonne L. Greenstreet, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
56.38K
+7.29%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
39.68K
+0.24%
Mr. Tolga Tanguler
Mr. Tolga Tanguler
Chief Commercial Officer
Chief Commercial Officer
15.33K
+5.62%
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
3.64K
-21.31%
Dr. Margaret A. Hamburg, M.D.
Dr. Margaret A. Hamburg, M.D.
Independent Director
Independent Director
136.00
-569.85%
Mr. David E. I. Pyott, CBE
Mr. David E. I. Pyott, CBE
Independent Director
Independent Director
--
--
Detalhamento da receita
Moeda: USDAtualizado em: seg, 6 de abr
Moeda: USDAtualizado em: seg, 6 de abr
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
Por EmpresaUSD
Nome
Receita
Proporção
AMVUTTRA
2.31B
62.30%
Roche
394.88M
10.63%
GIVLAARI
308.49M
8.31%
Other
218.55M
5.88%
OXLUMO
191.44M
5.15%
Outro
286.75M
7.72%
Por RegiãoUSD
Nome
Receita
Proporção
United States
2.07B
55.67%
Europe
651.09M
17.53%
Net revenues from collaborations
553.37M
14.90%
Rest of World
267.93M
7.21%
Royalty revenue
174.02M
4.69%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
AMVUTTRA
2.31B
62.30%
Roche
394.88M
10.63%
GIVLAARI
308.49M
8.31%
Other
218.55M
5.88%
OXLUMO
191.44M
5.15%
Outro
286.75M
7.72%
Distribuição de ações
Atualizado em: dom, 10 de mai
Atualizado em: dom, 10 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Capital World Investors
12.21%
Fidelity Management & Research Company LLC
11.30%
BlackRock Institutional Trust Company, N.A.
5.27%
Capital Research Global Investors
5.08%
Vanguard Portfolio Management, LLC
4.86%
Outro
61.28%
Investidores
Investidores
Proporção
Capital World Investors
12.21%
Fidelity Management & Research Company LLC
11.30%
BlackRock Institutional Trust Company, N.A.
5.27%
Capital Research Global Investors
5.08%
Vanguard Portfolio Management, LLC
4.86%
Outro
61.28%
Tipos de investidores
Investidores
Proporção
Investment Advisor
66.80%
Investment Advisor/Hedge Fund
22.94%
Hedge Fund
3.64%
Sovereign Wealth Fund
1.83%
Research Firm
1.79%
Pension Fund
1.47%
Bank and Trust
1.46%
Private Equity
0.22%
Individual Investor
0.17%
Participação acionária institucional
Atualizado em: dom, 5 de abr
Atualizado em: dom, 5 de abr
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2026Q1
1634
133.66M
100.11%
-6.05M
2025Q4
1441
132.38M
102.07%
-8.88K
2025Q3
1468
132.43M
102.39%
+2.53M
2025Q2
1335
129.81M
101.55%
+2.82M
2025Q1
1292
127.17M
99.72%
-2.77M
2024Q4
1248
125.34M
101.87%
-989.05K
2024Q3
1210
126.51M
99.20%
+3.13M
2024Q2
1165
122.70M
94.98%
+5.27M
2024Q1
1152
117.38M
97.56%
-6.00M
2023Q4
1149
120.10M
100.10%
-712.55K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Capital World Investors
16.30M
12.29%
-132.48K
-0.81%
Dec 31, 2025
Fidelity Management & Research Company LLC
15.08M
11.37%
-821.92K
-5.17%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
7.04M
5.31%
+453.92K
+6.89%
Dec 31, 2025
Capital Research Global Investors
6.78M
5.11%
-443.13K
-6.14%
Dec 31, 2025
JP Morgan Asset Management
4.00M
3.01%
+130.78K
+3.38%
Dec 31, 2025
State Street Investment Management (US)
3.23M
2.43%
+147.48K
+4.79%
Dec 31, 2025
Invesco Capital Management (QQQ Trust)
2.81M
2.12%
-68.68K
-2.39%
Feb 28, 2026
Geode Capital Management, L.L.C.
2.65M
2%
+151.48K
+6.06%
Dec 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: ter, 2 de dez
Atualizado em: ter, 2 de dez
Nome
Proporção
Global X Genomics & Biotechnology ETF
6.48%
ProShares Ultra Nasdaq Biotechnology
5.81%
Invesco Nasdaq Biotechnology ETF
5.77%
Franklin Genomic Advancements ETF
5.35%
iShares Biotechnology ETF
5.07%
VanEck Biotech ETF
4.56%
American Century Focused Dynamic Growth ETF
3.76%
Goldman Sachs Future Health Care Equity ETF
3.42%
First Trust NYSE Arca Biotechnology Index Fund
3.33%
Invesco NASDAQ Next Gen 100 ETF
3.28%
Ver Mais
Global X Genomics & Biotechnology ETF
Proporção6.48%
ProShares Ultra Nasdaq Biotechnology
Proporção5.81%
Invesco Nasdaq Biotechnology ETF
Proporção5.77%
Franklin Genomic Advancements ETF
Proporção5.35%
iShares Biotechnology ETF
Proporção5.07%
VanEck Biotech ETF
Proporção4.56%
American Century Focused Dynamic Growth ETF
Proporção3.76%
Goldman Sachs Future Health Care Equity ETF
Proporção3.42%
First Trust NYSE Arca Biotechnology Index Fund
Proporção3.33%
Invesco NASDAQ Next Gen 100 ETF
Proporção3.28%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
